Myoung Kuk Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Myoung Kuk Jang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Hak Yang Kim
Department of Internal Medicine Kangdong Sacred Heart Hospital of Hallym Universtiy Medical Center Seoul
11 shared publicationsJin Heon Lee
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
11 shared publicationsKyung Ho Kim
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
11 shared publicationsWoon Geon Shin
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
9 shared publicationsHyoung Su Kim
Department of Internal Medicine Kangdong Sacred Heart Hospital of Hallym Universtiy Medical Center Seoul
5 shared publications- Hyoung Su Kim
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
5 shared publications
Latest Publications
- 5 March 2015
- Published by Wiley in Helicobacter
- Vol. 20 (6) , 424-430
Is There Any Difference in the Eradication Rate ofHelicobacter pyloriInfection According to the Endoscopic Stage of Peptic Ulcer Disease?
Background The eradication rate of Helicobacter pylori (H. pylori) infection might be affected by the degree of inflammation of gastric mucosa represented by the endoscopic stage of peptic ulcer disease (PUD). The aims of this study were to evaluate the eradication rates of H. pylori infection according to the endoscopic stage of PUD and to document whether early eradication in the active stage could yield a higher eradication rate in patients with peptic ulcer bleeding (PUB). Materials and Methods A total of 1,177 patients with PUD (380 gastric ulcer, 710 duodenal ulcer, and 87 combined ulcer) who received proton‐pump inhibitor (PPI)‐based triple therapy were included, and the eradication rates were compared by ulcer stage. Univariate and multivariate analyses were conducted to identify factors influencing eradication rate. In PUB, the eradication rates between the early eradication group (≤7 days) and the late eradication group (>7 days) were compared. Results The eradication rates according to endoscopic stage were significantly different in gastric ulcer (active vs healing vs scarring; 84.8% vs 82.7% vs 70.6%, p = .014, respectively), but there were no significant differences in duodenal ulcer (active vs healing vs scarring; 87.6% vs 80.9%% vs 80.9% p = .169, respectively). In multivariate analyses, active ulcer as well as age younger than 50 was a significantly independent predictor of successful eradication (Odds ratio; 2.799, 95% CI; 1.659–4.723, p = .0001). The eradication rate of the early eradication group was significantly higher than the late eradication group in PUB (89.2% vs 71.9%, 95% CI; 1.265–8.269, p = .011). Conclusions There was a significant difference in the eradication rate according to the endoscopic stage of gastric ulcer. Active ulcer was an independent predictor of successful eradication. Furthermore, early H. pylori eradication should be considered in patients with PUB to yield a higher eradication rate.
- 5 March 2015
- Published by Wiley in Helicobacter
- Vol. 20 (6) , 424-430
Is There Any Difference in the Eradication Rate ofHelicobacter pyloriInfection According to the Endoscopic Stage of Peptic Ulcer Disease?
Background The eradication rate of Helicobacter pylori (H. pylori) infection might be affected by the degree of inflammation of gastric mucosa represented by the endoscopic stage of peptic ulcer disease (PUD). The aims of this study were to evaluate the eradication rates of H. pylori infection according to the endoscopic stage of PUD and to document whether early eradication in the active stage could yield a higher eradication rate in patients with peptic ulcer bleeding (PUB). Materials and Methods A total of 1,177 patients with PUD (380 gastric ulcer, 710 duodenal ulcer, and 87 combined ulcer) who received proton‐pump inhibitor (PPI)‐based triple therapy were included, and the eradication rates were compared by ulcer stage. Univariate and multivariate analyses were conducted to identify factors influencing eradication rate. In PUB, the eradication rates between the early eradication group (≤7 days) and the late eradication group (>7 days) were compared. Results The eradication rates according to endoscopic stage were significantly different in gastric ulcer (active vs healing vs scarring; 84.8% vs 82.7% vs 70.6%, p = .014, respectively), but there were no significant differences in duodenal ulcer (active vs healing vs scarring; 87.6% vs 80.9%% vs 80.9% p = .169, respectively). In multivariate analyses, active ulcer as well as age younger than 50 was a significantly independent predictor of successful eradication (Odds ratio; 2.799, 95% CI; 1.659–4.723, p = .0001). The eradication rate of the early eradication group was significantly higher than the late eradication group in PUB (89.2% vs 71.9%, 95% CI; 1.265–8.269, p = .011). Conclusions There was a significant difference in the eradication rate according to the endoscopic stage of gastric ulcer. Active ulcer was an independent predictor of successful eradication. Furthermore, early H. pylori eradication should be considered in patients with PUB to yield a higher eradication rate.
- 11 October 2013
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (1) , 124-130
Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: A retrospective cohort study
The simultaneous detection of hepatitis B surface antigen (HBsAg) and antibody to hepatitis B surface (anti‐HBs) is unusual in chronic hepatitis B virus (HBV) infection, but may be related with more advanced liver diseases. This retrospective long‐term cohort study was aimed to investigate whether coexistence of HBsAg and anti‐HBs may increase the risk of hepatocellular carcinoma (HCC) in chronic HBV infection. A total of 1,042 non‐HCC patients were recruited and followed up for a median 4.3 years (range 1.0–22 years). Univariate and multivariate analyses were performed to identify the risk factors for HCC development. The prevalence of coexistence of HBsAg and anti‐HBs was 7.0% (73/1,042). In univariate analysis, the 5‐, 10‐, and 15‐year cumulative incidences of HCC were significantly higher in coexistence group than in HBsAg only group (12.7%, 23.4%, 69.4% vs. 4.9%, 13%, 20.6%, respectively; P = 0.008). In multivariate analysis, coexistence of HBsAg and anti‐HBs [Hazard ratio (HR), 2.001; 95% confidence interval (CI), 1.023–3.912; P = 0.043] as well as male gender [HR, 1.898; 95% CI, 0.31–0.896; P = 0.018], age over 40 years [HR, 14.56; 95% CI, 4.499–47.08; P = 0.0001], and cirrhosis [HR, 7.995; 95% CI, 4.756–13.439; P = 0.0001] was identified as the independent factor for HCC development. Also, the cumulative incidence of HCC increased in proportion to the number of the risk factors. In conclusion, coexistence of HBsAg and anti‐HBs may increase independently the risk of HCC development in chronic HBV infection. Therefore, consideration of HCC development is required in patients with coexistence of HBsAg and anti‐HBs. J. Med. Virol. 86:124–130, 2014.
- 11 October 2013
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (1) , 124-130
Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: A retrospective cohort study
The simultaneous detection of hepatitis B surface antigen (HBsAg) and antibody to hepatitis B surface (anti‐HBs) is unusual in chronic hepatitis B virus (HBV) infection, but may be related with more advanced liver diseases. This retrospective long‐term cohort study was aimed to investigate whether coexistence of HBsAg and anti‐HBs may increase the risk of hepatocellular carcinoma (HCC) in chronic HBV infection. A total of 1,042 non‐HCC patients were recruited and followed up for a median 4.3 years (range 1.0–22 years). Univariate and multivariate analyses were performed to identify the risk factors for HCC development. The prevalence of coexistence of HBsAg and anti‐HBs was 7.0% (73/1,042). In univariate analysis, the 5‐, 10‐, and 15‐year cumulative incidences of HCC were significantly higher in coexistence group than in HBsAg only group (12.7%, 23.4%, 69.4% vs. 4.9%, 13%, 20.6%, respectively; P = 0.008). In multivariate analysis, coexistence of HBsAg and anti‐HBs [Hazard ratio (HR), 2.001; 95% confidence interval (CI), 1.023–3.912; P = 0.043] as well as male gender [HR, 1.898; 95% CI, 0.31–0.896; P = 0.018], age over 40 years [HR, 14.56; 95% CI, 4.499–47.08; P = 0.0001], and cirrhosis [HR, 7.995; 95% CI, 4.756–13.439; P = 0.0001] was identified as the independent factor for HCC development. Also, the cumulative incidence of HCC increased in proportion to the number of the risk factors. In conclusion, coexistence of HBsAg and anti‐HBs may increase independently the risk of HCC development in chronic HBV infection. Therefore, consideration of HCC development is required in patients with coexistence of HBsAg and anti‐HBs. J. Med. Virol. 86:124–130, 2014.
- 1 October 2013
- Vol. 60 (127) , 1592-6
Clinical significance of elevated serum alpha-fetoprotein (AFP) level in acute viral hepatitis A (AHA).
The clinical course of acute viral hepatitis A (AHA) is highly variable. Serum alphafetoprotein (AFP) level is often elevated in various types of acute liver injuries, indicating active liver regeneration. This study was aimed to investigate the clinical significance of serum AFP level in the aspect of the early recovery in AHA. A total of 238 patients with AHA, confirmed by IgM anti-hepatitis A virus, were included. The patients were classified according to serum AFP level. Multivariate analysis by Cox proportional hazards model using dichotomized clinical variables was performed to identify the independent predictors for early recovery (ALT normalization within 2 weeks). The median age (range) was 30 (17-50) years and male dominant (62%, 147/238). Compared to low AFP group, high AFP group (>10 ng/mL) had significantly lower platelet counts (p 10 ng/mL) was the only independent predictor for early recovery (Hazard ratio (HR); 2.392, 95% CI; 1.564-3.659, p = 0.0001). High serum AFP level (>10 ng/mL) may indicate the already-started recovery through active liver regeneration or the early recovery within 2 weeks in AHA.
- 1 October 2013
- Vol. 60 (127) , 1592-6
Clinical significance of elevated serum alpha-fetoprotein (AFP) level in acute viral hepatitis A (AHA).
The clinical course of acute viral hepatitis A (AHA) is highly variable. Serum alphafetoprotein (AFP) level is often elevated in various types of acute liver injuries, indicating active liver regeneration. This study was aimed to investigate the clinical significance of serum AFP level in the aspect of the early recovery in AHA. A total of 238 patients with AHA, confirmed by IgM anti-hepatitis A virus, were included. The patients were classified according to serum AFP level. Multivariate analysis by Cox proportional hazards model using dichotomized clinical variables was performed to identify the independent predictors for early recovery (ALT normalization within 2 weeks). The median age (range) was 30 (17-50) years and male dominant (62%, 147/238). Compared to low AFP group, high AFP group (>10 ng/mL) had significantly lower platelet counts (p 10 ng/mL) was the only independent predictor for early recovery (Hazard ratio (HR); 2.392, 95% CI; 1.564-3.659, p = 0.0001). High serum AFP level (>10 ng/mL) may indicate the already-started recovery through active liver regeneration or the early recovery within 2 weeks in AHA.
- 31 December 2011
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 74 (6) , 1422-1424
Pill-related esophageal intramural dissection treated by an endoscopic procedure
- 31 December 2011
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 74 (6) , 1422-1424
Pill-related esophageal intramural dissection treated by an endoscopic procedure
- 3 May 2011
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (7) , 1172-1177
Prevalence and clinical significance of hepatitis D virus co‐infection in patients with chronic hepatitis B in Korea
Hepatitis D virus (HDV) infection can cause severe acute and chronic liver disease in patients infected with hepatitis B virus (HBV). Despite the significant decline in the global HDV infection, it remains a major health concern in some countries. This study aimed to investigate the prevalence and clinical features of HDV co‐infection in patients with chronic HBV infection in Korea, where HBV infection is endemic. Nine hundred forty patients [median age, 48 (18–94) years; men, 64.5%] infected chronically with HBV were enrolled consecutively. All patients who were positive for hepatitis B surface antigen (HBsAg) for at least 6 months and were tested for anti‐HDV. A portion of the HDV delta antigen was amplified, sequenced, and subjected to molecular and phylogenetic analysis using sera from the patients who were anti‐HDV positive. Clinical features and virologic markers were evaluated. Inactive HBsAg carriers, chronic hepatitis B, cirrhosis and hepatocellular carcinoma accounted for 29.5%, 44.7%, 17.9%, and 8.0%, respectively. Only three patients were positive for anti‐HDV, corresponding to a 0.32% positive rate. All patients who were positive for anti‐HDV were inactive HBsAg carriers. HDV RNA could be amplified by PCR from the sera of two patients. Phylogenetic analysis showed that both carried HDV genotype 1. In conclusion, the prevalence of HDV infection is very low (0.32%) in Korea. All HDVs were genotype 1 and detected in inactive HBsAg carriers. Therefore, HDV co‐infection may not have a significant clinical impact in Korean patients with chronic HBV infection. J. Med. Virol. 83:1172–1177, 2011.
- 3 May 2011
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (7) , 1172-1177
Prevalence and clinical significance of hepatitis D virus co‐infection in patients with chronic hepatitis B in Korea
Hepatitis D virus (HDV) infection can cause severe acute and chronic liver disease in patients infected with hepatitis B virus (HBV). Despite the significant decline in the global HDV infection, it remains a major health concern in some countries. This study aimed to investigate the prevalence and clinical features of HDV co‐infection in patients with chronic HBV infection in Korea, where HBV infection is endemic. Nine hundred forty patients [median age, 48 (18–94) years; men, 64.5%] infected chronically with HBV were enrolled consecutively. All patients who were positive for hepatitis B surface antigen (HBsAg) for at least 6 months and were tested for anti‐HDV. A portion of the HDV delta antigen was amplified, sequenced, and subjected to molecular and phylogenetic analysis using sera from the patients who were anti‐HDV positive. Clinical features and virologic markers were evaluated. Inactive HBsAg carriers, chronic hepatitis B, cirrhosis and hepatocellular carcinoma accounted for 29.5%, 44.7%, 17.9%, and 8.0%, respectively. Only three patients were positive for anti‐HDV, corresponding to a 0.32% positive rate. All patients who were positive for anti‐HDV were inactive HBsAg carriers. HDV RNA could be amplified by PCR from the sera of two patients. Phylogenetic analysis showed that both carried HDV genotype 1. In conclusion, the prevalence of HDV infection is very low (0.32%) in Korea. All HDVs were genotype 1 and detected in inactive HBsAg carriers. Therefore, HDV co‐infection may not have a significant clinical impact in Korean patients with chronic HBV infection. J. Med. Virol. 83:1172–1177, 2011.
- 1 February 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (2) , 505-512
Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B
- 1 February 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (2) , 505-512
Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-808-808
M1906 Analysis of Factors Affecting HBeAg Early Seroconversion to anti-HBe in Acute Exacerbation of HBeAg Positive Chronic Hepatitis B with Genotype C; a Prospective Study
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-808-808
M1906 Analysis of Factors Affecting HBeAg Early Seroconversion to anti-HBe in Acute Exacerbation of HBeAg Positive Chronic Hepatitis B with Genotype C; a Prospective Study
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-807-807
M1905 Clinical Significance of Concurrent Hepatitis B Surface Antigen and Antibody Positivity in Chronic Hepatitis B Patients Based On Mutations of Pres Gene
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-807-807
M1905 Clinical Significance of Concurrent Hepatitis B Surface Antigen and Antibody Positivity in Chronic Hepatitis B Patients Based On Mutations of Pres Gene
- 3 April 2008
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (14) , e16
Ascariasis
Images in Clinical Medicine from The New England Journal of Medicine — Ascariasis
- 3 April 2008
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (14) , e16
Ascariasis
Images in Clinical Medicine from The New England Journal of Medicine — Ascariasis
- 1 January 2008
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 43 (1) , 81-88
Initial thrombocytopenia as a simple, valuable predictor for clinical manifestation in acute hepatitis A
Objective. Although acute hepatitis A (AH-A) is usually self-limited, the clinical manifestations can vary from mild to severe liver dysfunction. However, little is known about the simple, valuable predictors for clinical manifestation in AH-A. The objective of this study was to identify the simple clinical predictors for severe liver dysfunction and its clinical course. Material and methods. A total of 162 IgM anti-hepatitis A virus (HAV) positive patients were enrolled in the study. Severe AH-A was defined as a prothrombin time Results. Mean age (±SD) was 27.5 (±7.1) years and the proportion of males was 54% (88/162). Fourteen patients (8.7%) experienced severe AH-A. Of the liver-unrelated parameters, leukopenia (p p=0.033). Of the liver-related parameters, there were no independent predictors, as shown by multivariate analysis. The thrombocytopenia group (33%, 54/162) not only had a longer recovery time (28 days (range, 14–140) versus 37 days (20–128), pp=0.001) than the non-thrombocytopenia group. Conclusions. Initial thrombocytopenia may be a simple, valuable predictor for severity and clinical course in AH-A.
- 1 January 2008
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 43 (1) , 81-88
Initial thrombocytopenia as a simple, valuable predictor for clinical manifestation in acute hepatitis A
Objective. Although acute hepatitis A (AH-A) is usually self-limited, the clinical manifestations can vary from mild to severe liver dysfunction. However, little is known about the simple, valuable predictors for clinical manifestation in AH-A. The objective of this study was to identify the simple clinical predictors for severe liver dysfunction and its clinical course. Material and methods. A total of 162 IgM anti-hepatitis A virus (HAV) positive patients were enrolled in the study. Severe AH-A was defined as a prothrombin time Results. Mean age (±SD) was 27.5 (±7.1) years and the proportion of males was 54% (88/162). Fourteen patients (8.7%) experienced severe AH-A. Of the liver-unrelated parameters, leukopenia (p p=0.033). Of the liver-related parameters, there were no independent predictors, as shown by multivariate analysis. The thrombocytopenia group (33%, 54/162) not only had a longer recovery time (28 days (range, 14–140) versus 37 days (20–128), pp=0.001) than the non-thrombocytopenia group. Conclusions. Initial thrombocytopenia may be a simple, valuable predictor for severity and clinical course in AH-A.